Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | GLP1R | P43220 | 8/20 | 0.45 |
| ▸ | CASP2 | P42575 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640268 | 0.97 | GLP1R (0.48) | FAAHGLP1RCASP2NAAAEPHX2 | |
| SCHEMBL13640271 | 0.97 | GLP1R (0.48) | FAAHGLP1RCASP2NAAAEPHX2 | |
| SCHEMBL13640253 | 0.97 | FAAH (0.53) | FAAHGLP1RCASP2NAAAEPHX2 | |
| SCHEMBL17167854 | 0.91 | FAAH (0.46) | FAAHGLP1RCASP2NAAAEPHX2 | |
| SCHEMBL13640252 | 0.89 | FAAH (0.47) | FAAHGLP1RCASP2EPHX2TSHR | |
| SCHEMBL13640260 | 0.88 | MEN1 (0.49) | FAAHGLP1RCASP2NAAAEPHX2 | |
| SCHEMBL13640275 | 0.88 | GLP1R (0.46) | FAAHGLP1REPHX2TSHR | |
| SCHEMBL12743580 | 0.88 | FAAH (0.46) | FAAHGLP1RCASP2NAAAEPHX2 | |
| SCHEMBL19645170 | 0.88 | ADRA1A (0.53) | FAAHGLP1REPHX2 | |
| SCHEMBL13640267 | 0.87 | ADRA1A (0.47) | FAAHGLP1RCASP2PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210745-A1 | Double-Acylated GLP-1 Derivatives with a Linker | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | disclosed |
| US-9012398-B2 | Acylated exendin-4 compounds | NOVO NORDISK A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-9006178-B2 | Double-acylated GLP-1 derivatives with a linker | NOVO NORDISK A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-02-07 | — | — | US | disclosed |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210745-A1 | Double-Acylated GLP-1 Derivatives with a Linker | GLP1R, VIP, IAPP | FAAH 456/4885GLP1R 1/4885CASP2 977/4885 |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | GLP1R, VIP, IAPP | FAAH 163/4885GLP1R 1/4885CASP2 2065/4885 |
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GIPR, IAPP | FAAH 1269/4885GLP1R 1/4885CASP2 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.